CDC facing formidable challenges in convincing conservatives to get COVID-19 vaccines
Public health experts at the US Centers for Disease Control and Prevention are facing challenges even struggling as they try to figure out how to convince hesitant Republicans to take the COVID-19 vaccine, federal officials familiar with the situation told CNN.
“It’s kind of a mess to figure out with this particular audience what resonates with them, because they see vaccines as taking away their freedom,” said one official. “It’s a hard climb for everyone in public health. It’s moving a rock up a mountain.”
According to a Kaiser Family Foundation survey in April of more than 2,000 people in the US, 42% of Republicans, but only 19% of Democrats, are less than enthusiastic about getting the COVID-19 vaccine.
6 Fresh on the heels of a more than year-long effort to help combat the impact of the novel coronavirus pandemic, the U.S. Army Medical Research and Development Command’s Lt. Col. Michelle Colacicco-Mayhugh was honored as a 2021 Hero of Military Medicine award winner on May 6 at the Andrew W. Mellon Auditorium in Washington, D.C. The award, which recognizes outstanding contributions by individuals dedicated to advancing the ideals and reach of military medicine, is presented annually by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Calling the award a “tremendous honor” in her brief remarks to the small, select in-person audience – in addition to the hundreds in attendance online, viewing virtually – Colacicco-Mayhugh was quick to thank her coworkers, teammates and USAMRDC leadership for their respective roles in helping her achieve such a substantial accomplishment.
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
News provided by
Share this article
Up to 200,000 Johnson & Johnson
Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone
Company s Ebola vaccine regimen also receives Prequalification from the WHO
The Johnson & Johnson vaccine regimen is designed to be used proactively to induce immunity against Ebola in adults and children
NEW BRUNSWICK, N.J., May 13, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company s Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S,
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from.
Trial for
Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.
Findings from the Phase 2 Clinical Trial:
The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older, at 16 U.S. sites.
Participants received either INO-4800 (1.0 mg or 2.0 mg dose) or placebo at 0 and 4 weeks (randomized 3:3:1:1). Each dose was administered by intradermal injection followed by electroporation using INOVIO s CELLECTRA
®, its proprietary smart device.
Safety endpoints included systemic and local administration site reactions through 8 weeks post-dose one (or 4 weeks post-dose 2). Immunology endpoints included antigen-specific binding antibody titers, neutralization titers, and antigen-specific interferon-gamma (IFN-γ) cellular immune responses after two doses of the vaccine.